STOCK TITAN

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

Rhea-AI Summary
Accelera by Cummins, Daimler Trucks & Buses US Holding LLC, and PACCAR are partnering to accelerate and localize battery cell production in the United States. The joint venture will manufacture battery cells for electric commercial vehicles and industrial applications, with a total investment of $2-3 billion for a 21-gigawatt hour factory. The joint venture will initially focus on lithium-iron-phosphate battery technology for commercial electric trucks, offering advantages such as lower cost, longer life, and enhanced safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Merck announces positive results from the Phase 3 KEYNOTE-A18 trial, showing that KEYTRUDA in combination with concurrent chemoradiotherapy improves progression-free survival in patients with high-risk locally advanced cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Merck announces positive results from Phase 3 trial of KEYTRUDA in combination with chemotherapy for breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
Rhea-AI Summary
Merck announces positive results from the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA in combination with trastuzumab and chemotherapy for the treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Merck announces positive results from the Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA as a perioperative treatment regimen for resectable non-small cell lung cancer (NSCLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Daiichi Sankyo and Merck have entered into a global development and commercialization agreement for three antibody drug conjugate (ADC) candidates. Merck will pay Daiichi Sankyo a total potential consideration of up to $22 billion. The ADC candidates are in various stages of clinical development for the treatment of multiple solid tumors. Financial terms of the agreement include upfront payments and sales milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
Rhea-AI Summary
Merck's PREVYMIS receives positive recommendation from CHMP for the prevention of CMV disease in kidney transplant recipients and extended dosing for HSCT recipients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
-
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, has received FDA approval for the treatment of resectable non-small cell lung cancer (NSCLC) in combination with chemotherapy. The approval was based on positive results from a Phase 3 trial, showing statistically significant improvements in event-free survival and overall survival compared to placebo and chemotherapy. This marks the sixth indication for KEYTRUDA in NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
Merck & Co Inc

NYSE:MRK

MRK Rankings

MRK Stock Data

333.68B
2.53B
0.07%
78.61%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.